MedTrace Logo

Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation

NCT05052879 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2023-04-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Toronto association in the treatment of both sexual dysfunction: erectile dysfunction and premature ejaculation.

Conditions

Interventions

DRUG

Toronto association

Toronto association coated tablet, 20 mg + 30 mg or 20 mg + 60 mg, oral, 2 hours before the sexual intercourse.

DRUG

Tadalafil

Tadalafil coated tablet, 20 mg, oral, 2 hours before the sexual intercourse.

OTHER

Tadalafil placebo

Tadalafil placebo coated tablet, oral, 2 hours before the sexual intercourse.

OTHER

Toronto association placebo

Toronto association placebo coated tablet, oral, 2 hours before the sexual intercourse.

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-31
Primary Completion
2026-05-31
Completion
2026-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05052879 on ClinicalTrials.gov